WordNet

feel concern or interest; "I really care about my work"; "I dont care"
the work of providing treatment for or attending to someone or something; "no medical care was required"; "the old car needs constant attention" (同)attention, aid, tending
attention and management implying responsibility for safety; "he is in the care of a bodyguard" (同)charge, tutelage, guardianship
activity involved in maintaining something in good working order; "he wrote the manual on car care" (同)maintenance, upkeep
a cause for feeling concern; "his major care was the illness of his wife"
provide care for; "The nurse was caring for the wounded" (同)give care
of high social status; "people of quality"; "a quality family"
high social status; "a man of quality"
a degree or grade of excellence or worth; "the quality of students has risen"; "an executive of low caliber" (同)caliber, calibre
an essential and distinguishing attribute of something or someone; "the quality of mercy is not strained"--Shakespeare
a characteristic property that defines the apparent individual nature of something; "each town has a quality all its own"; "the radical character of our demands" (同)character, lineament
(Christianity) an assembly of theologians and bishops and other representatives of different churches or dioceses that is convened to regulate matters of discipline or doctrine
a body serving in an administrative capacity; "student council"
a meeting of people for consultation; "emergency council"
a healthy state of wellbeing free from disease; "physicians should be held responsible for the health of their patients" (同)wellness
the general condition of body and mind; "his delicate health"; "in poor health"

PrepTutorEJDIC

〈U〉『心配』,気がかり,悩み / 〈C〉《しばしば複数形で》心配事,苦労の種 / 〈U〉『細心の注意』,十二分の用心 / 〈U〉(…の)『世話』,監督,保護《+『for(of)+名』》 / 〈C〉関心事,気を配るべきこと / 『気にする』,心配する,関心がある / …『したいと思う』,欲する,好む
《時間・距離》『…の間』 / 《利益・貢献》『…のために』 / 《適応・用途》『…向きの(に);』…用の(に);…のための(に) / 《目的・意向》『…のために,』に / 《敬意・記念》『…のために;』…を記念して / 《獲得・追求》『…を得るために』,を求めて / 《行く先・方向》『…あてに;』…[方面]行きの,に向けて / 《交換・報償など》『…に対して』;…と引き換えに;…のお返しに / 《原因・理由》『…のために』,なので / 《代理・代表》『…の代わりに;』…を代表して / 《形容詞の後に用いて》『…にとって,』には / 《比較級の後に用いて》『…の結果として,』…のために / 《対比》『…としては,』のわりには / 《関連》『…について,』の点では / 《資格・属性》『…として』 / 《賛成・支持》…『に賛成して』,を支持して / 《傾向・好み》…『に対する』,には / 《模倣》《おもに米》《英文》…の名を取って(after) / 《割合》…に対して / 《『for』+『名』〈人〉+『to』 doの形で,〈人〉が不定詞to doの意味上の主語を表して》…が(…することは,…するために) / […というのは]…だから
〈C〉(人・物の)『特質』,『特性』《+of+名》 / 〈U〉(…の)『本質』(nature)《+『of』+『名』》 / 〈U〉『質』,品質 / 〈U〉良質(excellence),優秀性(superiority) / 〈U〉高い身分
諮問会,『協議会』,評議会・『会議』,協議 / 地方自治体の議会(州・市・町議会など)
『健康』,健全 / (体の)状態,調子 / 《To one's health!》(健康を祝しての)乾杯

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 緩和ケア：ナーシングホーム palliative care nursing home
2. 米国外の緩和ケアとホスピス palliative care and hospice outside of the united states
3. アドバンス・ケア・プランニングおよび事前指示 advance care planning and advance directives
4. うつ病のスクリーニング screening for depression
5. 緩和ケアにおけるうつ病の評価およびマネージメント assessment and management of depression in palliative care

English Journal

Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Ng M1, Fleming T1, Robinson M1, Thomson B1, Graetz N1, Margono C1, Mullany EC1, Biryukov S1, Abbafati C2, Abera SF3, Abraham JP4, Abu-Rmeileh NM5, Achoki T6, AlBuhairan FS7, Alemu ZA8, Alfonso R9, Ali MK10, Ali R11, Guzman NA12, Ammar W13, Anwari P14, Banerjee A15, Barquera S16, Basu S17, Bennett DA11, Bhutta Z18, Blore J19, Cabral N20, Nonato IC16, Chang JC21, Chowdhury R22, Courville KJ23, Criqui MH24, Cundiff DK25, Dabhadkar KC10, Dandona L26, Davis A27, Dayama A10, Dharmaratne SD28, Ding EL29, Durrani AM30, Esteghamati A31, Farzadfar F31, Fay DF27, Feigin VL32, Flaxman A1, Forouzanfar MH1, Goto A33, Green MA34, Gupta R35, Hafezi-Nejad N31, Hankey GJ36, Harewood HC37, Havmoeller R38, Hay S11, Hernandez L16, Husseini A39, Idrisov BT40, Ikeda N41, Islami F42, Jahangir E43, Jassal SK44, Jee SH45, Jeffreys M46, Jonas JB47, Kabagambe EK48, Khalifa SE49, Kengne AP50, Khader YS51, Khang YH52, Kim D53, Kimokoti RW54, Kinge JM55, Kokubo Y56, Kosen S57, Kwan G58, Lai T59, Leinsalu M60, Li Y61, Liang X62, Liu S62, Logroscino G63, Lotufo PA64, Lu Y29, Ma J62, Mainoo NK65, Mensah GA66, Merriman TR67, Mokdad AH1, Moschandreas J68, Naghavi M1, Naheed A69, Nand D70, Narayan KM10, Nelson EL1, Neuhouser ML71, Nisar MI18, Ohkubo T72, Oti SO73, Pedroza A16, Prabhakaran D74, Roy N75, Sampson U48, Seo H76, Sepanlou SG77, Shibuya K78, Shiri R79, Shiue I80, Singh GM29, Singh JA81, Skirbekk V55, Stapelberg NJ82, Sturua L83, Sykes BL84, Tobias M1, Tran BX85, Trasande L86, Toyoshima H87, van de Vijver S73, Vasankari TJ88, Veerman JL89, Velasquez-Melendez G90, Vlassov VV91, Vollset SE92, Vos T1, Wang C93, Wang X94, Weiderpass E95, Werdecker A96, Wright JL97, Yang YC98, Yatsuya H99, Yoon J100, Yoon SJ101, Zhao Y102, Zhou M61, Zhu S103, Lopez AD19, Murray CJ1, Gakidou E104.
Lancet.Lancet.2014 Aug 30;384(9945):766-81. doi: 10.1016/S0140-6736(14)60460-8. Epub 2014 May 29.
BACKGROUND: In 2010, overweight and obesity were estimated to cause 3·4 million deaths, 3·9% of years of life lost, and 3·8% of disability-adjusted life-years (DALYs) worldwide. The rise in obesity has led to widespread calls for regular monitoring of changes in overweight and obesity prevalence
PMID 24880830

Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk.

Lin WY1, Camp NJ2, Ghoussaini M3, Beesley J4, Michailidou K3, Hopper JL5, Apicella C5, Southey MC6, Stone J7, Schmidt MK8, Broeks A8, Van't Veer LJ8, Th Rutgers EJ8, Muir K9, Lophatananon A10, Stewart-Brown S10, Siriwanarangsan P11, Fasching PA12, Haeberle L13, Ekici AB14, Beckmann MW13, Peto J15, Dos-Santos-Silva I15, Fletcher O16, Johnson N16, Bolla MK3, Wang Q3, Dennis J3, Sawyer EJ17, Cheng T18, Tomlinson I18, Kerin MJ19, Miller N19, Marmé F20, Surowy HM21, Burwinkel B21, Guénel P22, Truong T22, Menegaux F22, Mulot C23, Bojesen SE24, Nordestgaard BG24, Nielsen SF25, Flyger H26, Benitez J27, Zamora MP28, Arias Perez JI29, Menéndez P30, González-Neira A31, Pita G31, Alonso MR31, Alvarez N31, Herrero D31, Anton-Culver H32, Brenner H33, Dieffenbach AK33, Arndt V34, Stegmaier C35, Meindl A36, Lichtner P37, Schmutzler RK38, Müller-Myhsok B39, Brauch H40, Brüning T41, Ko YD42; The GENICA Network, Tessier DC43, Vincent D43, Bacot F43, Nevanlinna H44, Aittomäki K45, Blomqvist C46, Khan S44, Matsuo K47, Ito H48, Iwata H49, Horio A49, Bogdanova NV50, Antonenkova NN51, Dörk T52, Lindblom A53, Margolin S54, Mannermaa A55, Kataja V56, Kosma VM55, Hartikainen JM55; kConFab Investigators; Australian Ovarian Cancer Study Group, Wu AH57, Tseng CC57, Van Den Berg D57, Stram DO57, Neven P58, Wauters E59, Wildiers H60, Lambrechts D61, Chang-Claude J62, Rudolph A62, Seibold P62, Flesch-Janys D63, Radice P64, Peterlongo P65, Manoukian S66, Bonanni B67, Couch FJ68, Wang X68, Vachon C69, Purrington K70, Giles GG71, Milne RL71, Mclean C72, Haiman CA57, Henderson BE57, Schumacher F57, Le Marchand L73, Simard J74, Goldberg MS75, Labrèche F76, Dumont M74, Teo SH77, Yip CH78, Hassan N77, Vithana EN79, Kristensen V80, Zheng W81, Deming-Halverson S81, Shrubsole MJ81, Long J81, Winqvist R82, Pylkäs K82, Jukkola-Vuorinen A83, Kauppila S84, Andrulis IL85, Knight JA86, Glendon G87, Tchatchou S88, Devilee P89, Tollenaar RA90, Seynaeve C91, Van Asperen CJ92, García-Closas M93, Figueroa J94, Lissowska J95, Brinton L94, Czene K96, Darabi H96, Eriksson M96, Brand JS96, Hooning MJ91, Hollestelle A91, Van Den Ouweland AM97, Jager A91, Li J98, Liu J99, Humphreys K96, Shu XO81, Lu W98, Gao YT100, Cai H81, Cross SS101, Reed MW102, Blot W103, Signorello LB103, Cai Q81, Pharoah PD104, Perkins B105, Shah M105, Blows FM105, Kang D106, Yoo KY107, Noh DY108, Hartman M109, Miao H110, Chia KS110, Putti TC111, Hamann U112, Luccarini C105, Baynes C105, Ahmed S105, Maranian M105, Healey CS105, Jakubowska A113, Lubinski J113, Jaworska-Bieniek K113, Durda K113, Sangrajrang S114, Gaborieau V115, Brennan P115, Mckay J115, Slager S69, Toland AE116, Yannoukakos D117, Shen CY118, Hsiung CN119, Wu PE120, Ding SL121, Ashworth A122, Jones M123, Orr N124, Swerdlow AJ125, Tsimiklis H126, Makalic E127, Schmidt DF127, Bui QM127, Chanock SJ94, Hunter DJ128, Hein R129, Dahmen N130, Beckmann L131, Aaltonen K44, Muranen TA44, Heikkinen T44, Irwanto A99, Rahman N123, Turnbull CA123; The Breast and Ovarian Cancer Susceptibility (BOCS) Study, Waisfisz Q132, Meijers-Heijboer HE132, Adank MA132, Van Der Luijt RB133, Hall P96, Chenevix-Trench G4, Dunning A105, Easton DF104, Cox A134.
Human molecular genetics.Hum Mol Genet.2014 Aug 28. pii: ddu431. [Epub ahead of print]
Previous studies have suggested that polymorphisms in CASP8 on chromosome 2 are associated with breast cancer risk. To clarify the role of CASP8 in breast cancer susceptibility, we carried out dense genotyping of this region in the Breast Cancer Association Consortium (BCAC). Single-nucleotide polym
PMID 25168388

Integrated care pathways for airway diseases (AIRWAYS-ICPs).

European Innovation Partnership on Active and Healthy Ageing, Action Plan B3; Mechanisms of the Development of Allergy, WP 10; Global Alliance against Chronic Respiratory Diseases, Bousquet J1, Addis A2, Adcock I3, Agache I4, Agusti A5, Alonso A6, Annesi-Maesano I7, Anto JM8, Bachert C9, Baena-Cagnani CE10, Bai C11, Baigenzhin A12, Barbara C13, Barnes PJ3, Bateman ED14, Beck L15, Bedbrook A16, Bel EH17, Benezet O18, Bennoor KS19, Benson M20, Bernabeu-Wittel M21, Bewick M22, Bindslev-Jensen C23, Blain H24, Blasi F25, Bonini M26, Bonini S27, Boulet LP28, Bourdin A29, Bourret R30, Bousquet PJ7, Brightling CE31, Briggs A32, Brozek J33, Buhl R34, Bush A35, Caimmi D36, Calderon M37, Calverley P38, Camargos PA39, Camuzat T18, Canonica GW40, Carlsen KH41, Casale TB7, Cazzola M42, Cepeda Sarabia AM43, Cesario A44, Chen YZ45, Chkhartishvili E46, Chavannes NH47, Chiron R36, Chuchalin A48, Chung KF3, Cox L49, Crooks G50, Crooks MG51, Cruz AA52, Custovic A53, Dahl R23, Dahlen SE54, De Blay F55, Dedeu T56, Deleanu D57, Demoly P58, Devillier P59, Didier A60, Dinh-Xuan AT61, Djukanovic R62, Dokic D63, Douagui H64, Dubakiene R65, Eglin S66, Elliot F67, Emuzyte R65, Fabbri L68, Fink Wagner A69, Fletcher M70, Fokkens WJ71, Fonseca J72, Franco A73, Frith P74, Furber A75, Gaga M76, Garcés J77, Garcia-Aymerich J8, Gamkrelidze A78, Gonzales-Diaz S79, Gouzi F80, Guzmán MA81, Haahtela T82, Harrison D83, Hayot M24, Heaney LG84, Heinrich J85, Hellings PW86, Hooper J87, Humbert M88, Hyland M89, Iaccarino G90, Jakovenko D18, Jardim JR91, Jeandel C24, Jenkins C92, Johnston SL93, Jonquet O24, Joos G94, Jung KS95, Kalayci O96, Karunanithi S97, Keil T98, Khaltaev N99, Kolek V100, Kowalski ML101, Kull I102, Kuna P103, Kvedariene V104, Le LT105, Lodrup Carlsen KC41, Louis R106, MacNee W107, Mair A108, Majer I109, Manning P110, de Manuel Keenoy E111, Masjedi MR112, Melen E113, Melo-Gomes E13, Menzies-Gow A114, Mercier G24, Mercier J115, Michel JP116, Miculinic N117, Mihaltan F118, Milenkovic B119, Molimard M120, Momas I121, Montilla-Santana A122, Morais-Almeida M123, Morgan M124, N'Diaye M125, Nafti S126, Nekam K127, Neou A128, Nicod L129, O'Hehir R130, Ohta K131, Paggiaro P132, Palkonen S133, Palmer S134, Papadopoulos NG135, Papi A136, Passalacqua G40, Pavord I137, Pigearias B138, Plavec D139, Postma DS140, Price D141, Rabe KF142, Radier Pontal F18, Redon J143, Rennard S144, Roberts J145, Robine JM146, Roca J5, Roche N147, Rodenas F77, Roggeri A148, Rolland C149, Rosado-Pinto J150, Ryan D151, Samolinski B152, Sanchez-Borges M153, Schünemann HJ154, Sheikh A155, Shields M156, Siafakas N157, Sibille Y158, Similowski T159, Small I160, Sola-Morales O161, Sooronbaev T162, Stelmach R163, Sterk PJ17, Stiris T164, Sud P165, Tellier V166, To T167, Todo-Bom A168, Triggiani M169, Valenta R170, Valero AL5, Valiulis A171, Valovirta E172, Van Ganse E173, Vandenplas O174, Vasankari T175, Vestbo J176, Vezzani G177, Viegi G178, Visier L24, Vogelmeier C179, Vontetsianos T180, Wagstaff R181, Wahn U182, Wallaert B183, Whalley B89, Wickman M113, Williams DM184, Wilson N185, Yawn BP186, Yiallouros PK187, Yorgancioglu A188, Yusuf OM189, Zar HJ190, Zhong N191, Zidarn M192, Zuberbier T128.
The European respiratory journal.Eur Respir J.2014 Aug;44(2):304-23. doi: 10.1183/09031936.00014614. Epub 2014 Jun 12.
The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will ad
PMID 24925919

Japanese Journal

緩和ケア病棟の入院判定の適正化，公正化の試み―入院必要度のスコア化のためのチェックリストの導入―

木元道雄,岸本寛文,西ひろみ
Palliative Care
がんによる死亡数が年々増加する中，ホスピス・緩和ケア病棟（以下，PCU）のベッド数は未だに不足しておりPCU を医療資源として有効に活用するためには適切で公正な入院判定が重要となる．厚生労働省の緩和ケア病棟入院料の施設基準や病院評価機構の緩和ケア機能の評価項目でも入院判定を適切に行うことを求めている．多くのPCU では入院判定会議が設置されているものの，入院の優先順位を決める明確な基準を公表してい …
NAID 130004943689

イギリスにおける専門職の実践適合性(Fitness to practise)検討プロセス : The Health and Care Professions Councilの実践より

白旗希実子,鈴木道子
産業教育学研究 44(2), 9-17, 2014-07-31
本研究の目的は、イギリスにおける専門職の規制機関であるHCPCが実施する、実践適合性の検討プロセスとその意味を明らかにすることである。その結果、HCPCの実践適合性の検討プロセスは、専門職団体のみに任せず、公衆の視点も取り込んだ上で、重層的に専門職の品質を判断するシステムであることが明らかとなり、専門職の品質保証に実質的内容を与えるという意味合いも持ち合わせている可能性が示唆された。
NAID 110009833428